{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwon M"],"funding":["National Research Foundation of Korea"],"pagination":["2944-2956"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359877"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(15)"],"pubmed_abstract":["<h4>Background</h4>Patients with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell-free plasma DNA (cfDNA) next-generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor (TKI) therapy in ALK+ NSCLC.<h4>Methods</h4>Patients with ALK+ NSCLC determined by standard tissue testing and planned to undergo TKI therapy were prospectively recruited. Plasma was collected at pretreatment, 2 months-post therapy, and at progression for cfDNA-NGS analysis, Guardant 360.<h4>Results</h4>Among 92 patients enrolled, circulating tumor DNA (ctDNA) was detected in 69 baseline samples (75%): 43 ALK fusions (62.3%) and two ALK mutations without fusion (2.8%). Two patients showed ALK-resis"],"journal":["Cancer medicine"],"pubmed_title":["Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors."],"pmcid":["PMC9359877"],"funding_grant_id":["NRF‐2017M3A9G5060259"],"pubmed_authors":["Ahn MJ","Sun JM","Odegaard J","Kwon M","Jung HA","Ahn JS","Park K","Ku BM","Lee SH","Olsen S","Park S","Lefterova M"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.","description":"<h4>Background</h4>Patients with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell-free plasma DNA (cfDNA) next-generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor (TKI) therapy in ALK+ NSCLC.<h4>Methods</h4>Patients with ALK+ NSCLC determined by standard tissue testing and planned to undergo TKI therapy were prospectively recruited. Plasma was collected at pretreatment, 2 months-post therapy, and at progression for cfDNA-NGS analysis, Guardant 360.<h4>Results</h4>Among 92 patients enrolled, circulating tumor DNA (ctDNA) was detected in 69 baseline samples (75%): 43 ALK fusions (62.3%) and two ALK mutations without fusion (2.8%). Two patients showed ALK-resis","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-27T19:11:19.7Z","creation":"2025-02-19T03:23:24.747Z"},"accession":"S-EPMC9359877","cross_references":{"pubmed":["35437925"],"doi":["10.1002/cam4.4663"]}}